Key Highlights

  • NovoCure (NASDAQ:NVCR) disclosed on November 9, 2026 that the FDA had returned a not approvable letter on its premarket approval request for Optune Mya in brain metastases arising from non-small cell lung cancer.
  • The request covered adults whose brain metastases had received stereotactic radiation, with the device intended to follow radiation and slow further spread within the brain.
  • The agency pointed to uncertainty about how much clinical benefit the device provides and raised no safety concerns in its reply to the company.
  • NovoCure intends to meet with the FDA to explore paths that avoid new clinical studies, while cautioning that approval is far from assured.

A Setback Rooted in Benefit, Not Safety

A not approvable letter means a significant blow for NovoCure (NASDAQ:NVCR), since the agency concluded the submitted data fall short of supporting approval as they stand. The device, which applies tumor treating fields via electrodes placed on the scalp, already holds approval for glioblastoma under the Optune name, and the brain metastases filing aimed to reach a far bigger patient pool. Lung cancer is the leading origin of brain metastases, and many patients undergo targeted radiation and then observation, so an add-on treatment that slows progression could find wide application. The FDA's objection concerned the magnitude of the benefit rather than safety, a gap that invites further discussion but also raises a central question about how persuasive the trial results were. The decision also takes away a catalyst that investors had counted on for growth in coming years and adds doubt about the company's medium-term plan.

Routes Around a New Trial and Other Growth Drivers

NovoCure is weighing the FDA's feedback and hopes to pursue approaches that skip another study, such as more analysis of current data, a tighter patient group or commitments after approval. Device reviewers have more room than drug reviewers in certain instances, yet a letter of this kind is generally hard to overturn without fresh evidence. The company has additional programs supporting its growth. Japan approved Optune Pax for locally advanced pancreatic cancer effective October 1, 2026, while NovoCure raised 2026 guidance with its October 29 third-quarter report. These factors preserve Revenue momentum in established markets while it works through the brain metastases question. Management has not given a schedule for the FDA meeting or any resubmission, leaving the timing of a decision open.

Study Requirements, Pancreatic Filing and Communication

The chief danger is that NovoCure (NASDAQ:NVCR) finds no approval route short of a fresh study, which would push the indication back several years and raise costs. Investors had built brain metastases into long-range revenue forecasts, so the letter trims the anticipated size of the addressable market. Similar doubts about benefit magnitude could influence how regulators treat other indications under development, including its pancreatic program in the United States. Market watchers should follow the result of the scheduled FDA session, any comments on whether a resubmission is viable, Optune Pax adoption in Japan and advancement of the US pancreatic filing. The way NovoCure explains its regulatory path over the coming weeks will influence confidence in its long-term strategy.

Where Things Stand

NovoCure (NASDAQ:NVCR) was handed a not approvable decision on Optune Mya for brain metastases stemming from lung cancer on November 9, 2026, as the agency flagged doubt about how much benefit the device delivers instead of any safety problem. The firm will look for an approach that sidesteps a new trial, although approval is far from guaranteed. Its glioblastoma Franchise and the Japanese pancreatic clearance keep revenue flowing.